PTG fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
PolTREG SA develops and commercializes patented TREG methods. It engages in the research, development, implementation, and commercialization of T-regulatory lymphocytes and using their growth method for clinical use to treat type 1 diabetes. The company was founded in 2015 by Piotr Trzonkowski, Malgorzata Mysliwiec, Wojciech Tadeusz Kakol and Natalia Maria Marek Trzonkowska and is headquartered in Gdansk, Poland.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
PTG does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company